[go: up one dir, main page]

AR057643A1 - LACOSAMIDE FOR ATTACHED THERAPY - Google Patents

LACOSAMIDE FOR ATTACHED THERAPY

Info

Publication number
AR057643A1
AR057643A1 ARP060100304A ARP060100304A AR057643A1 AR 057643 A1 AR057643 A1 AR 057643A1 AR P060100304 A ARP060100304 A AR P060100304A AR P060100304 A ARP060100304 A AR P060100304A AR 057643 A1 AR057643 A1 AR 057643A1
Authority
AR
Argentina
Prior art keywords
lacosamide
therapy
attached
attached therapy
antipsychotics
Prior art date
Application number
ARP060100304A
Other languages
Spanish (es)
Inventor
Thomas Stohr
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05001843A external-priority patent/EP1688137A1/en
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of AR057643A1 publication Critical patent/AR057643A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Uso de una clase de compuestos péptidos para la prevencion, alivio y/o tratamiento de una enfermedad tratada con antipsicoticos, en particular psicosis, más particularmente, esquizofrenia, en una terapia adjunta a al menos un antipsicotico.Use of a class of peptide compounds for the prevention, relief and / or treatment of a disease treated with antipsychotics, in particular psychosis, more particularly, schizophrenia, in a therapy attached to at least one antipsychotic.

ARP060100304A 2005-01-28 2006-01-27 LACOSAMIDE FOR ATTACHED THERAPY AR057643A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64741005P 2005-01-28 2005-01-28
EP05001843A EP1688137A1 (en) 2005-01-28 2005-01-28 SPM 927 for add-on therapy of schizophrenia

Publications (1)

Publication Number Publication Date
AR057643A1 true AR057643A1 (en) 2007-12-12

Family

ID=36636204

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100304A AR057643A1 (en) 2005-01-28 2006-01-27 LACOSAMIDE FOR ATTACHED THERAPY

Country Status (12)

Country Link
EP (1) EP1841417A2 (en)
JP (1) JP2008528532A (en)
KR (1) KR20070096058A (en)
AR (1) AR057643A1 (en)
AU (1) AU2006208630B2 (en)
BR (1) BRPI0607043A2 (en)
CA (1) CA2595330A1 (en)
EA (1) EA015566B1 (en)
IL (1) IL183973A0 (en)
MX (1) MX2007009070A (en)
NO (1) NO20074361L (en)
WO (1) WO2006079547A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007144195A2 (en) 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
EP1920780A1 (en) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptide compounds for the treatment of hyperexcitability disorders
CN101466390B (en) 2006-06-15 2014-03-12 优时比制药有限公司 Peptide compounds for the treatment of refractory status epilepticus
EP1873527A1 (en) 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
US20100260716A1 (en) 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
US20100151021A1 (en) * 2008-12-16 2010-06-17 Venkatesh Gopi M Compositions Comprising Melperone
WO2012084126A2 (en) 2010-12-02 2012-06-28 Ucb Pharma Gmbh Formulation of lacosamide
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
CN110087641B (en) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 Transdermal therapeutic systems containing asenapine and polysiloxane or polyisobutylene
KR102506333B1 (en) 2016-12-20 2023-03-06 에르테에스 로만 테라피-시스테메 아게 Transdermal absorption treatment system containing asenapine
EP3644973B1 (en) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
CN118593482A (en) 2017-12-05 2024-09-06 赛诺维信制药公司 Non-racemic mixture and its use
KR20200110317A (en) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 Crystal form and method for preparing the same
CN112533593A (en) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 Transdermal therapeutic system comprising asenapine
CN112704672A (en) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 Transdermal therapeutic system comprising asenapine
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
US11278634B1 (en) 2021-02-12 2022-03-22 Extrovis Ag Stable parenteral composition of lacosamide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
PT1243262E (en) 2001-03-20 2006-10-31 Sanol Arznei Schwarz Gmbh NEW USE OF A CLASS OF PEPTIDE COMPOUNDS FOR THE TREATMENT OF NON-NEUROPATHIC INFLAMMATORY PAIN
DE60100055T2 (en) 2001-03-21 2003-07-24 Schwarz Pharma Ag New use of a class of peptide compounds for the treatment of allodynia or other types of chronic or phantom pain

Also Published As

Publication number Publication date
EA015566B1 (en) 2011-10-31
JP2008528532A (en) 2008-07-31
KR20070096058A (en) 2007-10-01
NO20074361L (en) 2007-10-26
CA2595330A1 (en) 2006-08-03
EP1841417A2 (en) 2007-10-10
AU2006208630A1 (en) 2006-08-03
EA200701594A1 (en) 2008-02-28
MX2007009070A (en) 2007-09-12
BRPI0607043A2 (en) 2009-08-04
AU2006208630B2 (en) 2011-09-29
WO2006079547A2 (en) 2006-08-03
IL183973A0 (en) 2008-12-29
WO2006079547A3 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
AR057643A1 (en) LACOSAMIDE FOR ATTACHED THERAPY
CY1122522T1 (en) META ARSENICODE SODIUM FOR USE IN THE MANAGEMENT OF MULTIPLE MYELOMA
NL300936I2 (en) Semaglutide
CL2007002384A1 (en) Use of compounds derived from 2,5-dihydroxybenzene for the treatment of psoriasis.
CL2008001234A1 (en) COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES, INHIBITORS OF APOPTOSIS PROTEINS; AND USE IN THE TREATMENT OF CANCER.
CL2008001076A1 (en) COMPOUNDS DERIVED FROM SULFONAMIDE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
NO20053051D0 (en) Fatigue reducing agent.
PA8637201A1 (en) DIFENYLIMIDAZOPIRIMIDINE E-IMIDAZOL AMINAS AS INHIBITORS OF B-SECRETASE
CL2009001099A1 (en) Use of a human interleukin-2 mutein for the treatment and / or prevention of an autoimmune disease.
AR061446A1 (en) USE OF 1,7-DIMETHYLXANTINE FOR THE MANUFACTURE OF A NON-ANIOIOUS PSYCHOANALEPTIC DRUG FOR THE TREATMENT OF A NEUROPSYCHIATRIC DISORDER
ATE481984T1 (en) VACCINE-PEPTIDE COMBINATIONS AGAINST CAT ALLERGY
BRPI0719345A2 (en) REPLACED DI-HYDROIMIDAZOLS AND ITS USE IN TREATMENT TREATMENT.
CL2007002380A1 (en) Use of compounds derived from 2,5-dihydroxybenzene for the therapeutic and / or prophylactic treatment of actinic keratosis.
FR2864552B1 (en) SURFACE TREATMENT WITH HYDROXYSULFATE
WO2008028963A3 (en) Calreticulin for its use as a medication for the treatment of cancer in a mammal
UY28344A1 (en) NEW COMPOUNDS
AR058173A1 (en) USE OF SDF-1 FOR THE TREATMENT AND / OR PREVENTION OF NEUROLOGICAL DISEASES
CL2008000865A1 (en) COMPOUNDS DERIVED FROM BENZIMIDAZOL-2-ONA; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF A PSYCHOTIC DISORDER OR A COGNITIVE DETERIORATION.
TW200637538A (en) Lacosamide for add-on-therapy
UY29417A1 (en) ENDOPARASITICID AGENTS
DE10394003D2 (en) Textile treatment agents
DK1838716T3 (en) Olanzapinpamota dihydrate
ATE404725T1 (en) TEXTILE TREATMENT
RU2005119153A (en) MEANS OF TREATMENT OF ACUTE RADIATING DISEASE
ITTV20050186A1 (en) BED FOR BODY TANNING.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal